Company: HURA
Filing Date: 2025-12-10
Form Type: 424B5
Source: 0001193125-25-313799
Chunk: 1

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-12-10
Form: 424B5
Chunk 1
---
. The second closing of the offering is expected to occur by no later than January 30, 2026, with the first expected to occur on December 10, 2025
with all investors in the offering other than K&V. At the second closing, the Company will issue an aggregate of 3,030,303 shares of its Common Stock, Series A Warrants to purchase up to an aggregate of 3,030,303 shares of its Common Stock and
Series B Warrants to purchase up to an aggregate of 3,030,303 shares of its Common Stock to K&V. The third closing of the offering is expected to occur by no later than February 27, 2026. At the third closing, the Company will issue an
aggregate of 1,212,121 shares of its Common Stock, Series A Warrants to purchase up to an aggregate of 1,212,121 shares of its Common Stock and Series B Warrants to purchase up to an aggregate of 1,212,121 shares of its Common Stock. All Warrants
received by K&V will be exercisable starting on the six month anniversary from the date of issuance, but the Series A Warrants received and the Series B Warrants received by K&V will still expire five and a half years and two years after the
first closing of this offering, respectively. Vijay Patel, who is an affiliate of K&V, is our largest shareholder and, as of September 11, 2025, beneficially owns approximately 25.5% of our issued and outstanding Common Stock.

There is no established public trading market for the Warrants and we do not expect a market to develop. We do not intend to apply for listing
of the Warrants on any securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the Warrants will be limited.

Our Common Stock is traded on the Nasdaq Capital Market under the symbol “HURA.” On December 8, 2025, the last reported sales
price of our Common Stock was $1.98 per share.

We have retained H.C. Wainwright & Co., LLC to act as the exclusive lead
placement agent in connection with this offering and Rodman & Renshaw LLC is acting as co-placement agent for the offering (the “placement agents”). The placement agents are not purchasing
or selling any of the shares of Common Stock or Warrants but

have agreed to use their